Immunotherapeutic method to prevent islet cell rejection
OwnerBernhard J. Hering, Martin Wijkstrom +1inventors
InventorsBernhard J. Hering, Martin Wijkstrom, Nicole Kirchhof
Life of this patent
Estimating the term…
Abstract
A method for the prevention or reversal of islet cell transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to CD40L and the CD4 receptor.
Claims20
A method for treating or preventing islet cell transplant rejection in a mammalian recipient, comprising administering to the recipient a combination of an antibody, fragment thereof, or mixture thereof that specifically binds to the CD40 ligand, and an antibody, fragment thereof, or mixture thereof that specifically binds to the CD4 receptor, in an amount of the combination effective to inhibit a T-cell mediated immune response in the recipient to the islet cell transplant.
A method for treating an autoimmune disease, comprising administering to a mammal afflicted with an autoimmune disease, a combination of an amount of at least one compound which specifically binds to the CD40 ligand, and an amount of at least one compound which specifically binds to the CD4 molecule, wherein the amounts are effective to inhibit a T-cell mediated immune response.
Dependencies are inferred from the claim text.